Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Eribulin as 1st Line Treatment in Elderly Patients (≥ 70 Years) With Advanced Breast Cancer: a Multicenter Phase II Trial

NCT02404506 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT02404506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02404506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Eribulin as 1st Line Treatment in Elderly Patients (≥ 70 Years) With Advanced Breast Cancer: a Multicenter Phase II Trial
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Terminated
Start date
August 17, 2015
Completion date
July 22, 2021
Enrollment
78 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma, breast cancer